These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1423 related items for PubMed ID: 21875310

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
    Weiner RA.
    Dig Dis; 2010; 28(1):274-9. PubMed ID: 20460923
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ, Chitturi S, Heydet D, Farrell GC.
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Diagnosis and therapy in NASH].
    Tokushige K.
    Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
    [Abstract] [Full Text] [Related]

  • 30. Non-alcoholic fatty liver disease.
    Leclercq I.
    Bull Mem Acad R Med Belg; 2010 Sep; 165(3-4):147-55; discussion 155-8. PubMed ID: 21166266
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
    Musso G, Gambino R, Cassader M, Pagano G.
    Ann Med; 2011 Dec; 43(8):617-49. PubMed ID: 21039302
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT, de Oliveira CP, Corrêa-Giannella ML, Soares IC, Kubrusly MS, Bellodi-Privato M, de Mello ES, de Lima VM, Carrilho FJ, Alves VA.
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [Abstract] [Full Text] [Related]

  • 35. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C.
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 72.